Related Experiment Video
Updated: Apr 26, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Cutaneous erosions: a herald for impending pancytopenia in methotrexate toxicity
Mallory B Shiver1, Lauren A Hall, Kelly B Conner
1The University of Arkansas for Medical Sciences.
Abstract:
Psoriatic plaque erosion is a rare toxic side effect of low-dose methotrexate (LDMTX) that has been reported during the treatment of psoriasis and described as a herald for impending pancytopenia. Fatalities from this have rarely been reported. Even rarer is methotrexate (MTX)-induced erosions of clinically normal skin in patients without a history of psoriasis. We report 3 rare presentations of MTX-induced cutaneous erosions, 2 fatalities occurring with MTX-induced psoriatic plaque erosions, and the sixth reported case of MTX-induced erosions with no prior history of psoriasis. Each were elderly patients on proton pump inhibitors with a history of chronic non-steroidal anti-inflammatory drug (NSAID) use. They all presented with acute onset of erosions after a recent change in their MTX dose. Pancytopenia followed in each case. Physicians' awareness of the sequelae in MTX-induced cutaneous erosions is imperative so MTX can be discontinued and treatment instituted to prevent fatal bone marrow suppression.
Insights
Methotrexate (MTX) can cause rare skin erosions, sometimes leading to fatal pancytopenia, even in patients without psoriasis. Early recognition and MTX discontinuation are crucial for preventing severe outcomes.
Area of Science:
- Dermatology
- Hematology
- Toxicology
Background:
- Low-dose methotrexate (LDMTX) is used for psoriasis treatment.
- MTX toxicity can manifest as psoriatic plaque erosions, a rare side effect.
- These erosions may herald impending pancytopenia.
Observation:
- This report details three rare cases of MTX-induced cutaneous erosions.
- Two cases involved fatal MTX-induced psoriatic plaque erosions.
- One case presented with MTX-induced erosions in clinically normal skin without a psoriasis history.
Findings:
- All patients were elderly, on proton pump inhibitors, and had a history of NSAID use.
- Erosions appeared acutely after a change in MTX dosage.
- Pancytopenia followed the onset of skin erosions in all reported cases.
Implications:
- Physicians must be aware of MTX-induced cutaneous erosions as a potential sign of bone marrow suppression.
- Prompt discontinuation of MTX and initiation of treatment are vital.
- Increased physician awareness can prevent fatal outcomes associated with MTX toxicity.
More Related Videos
Related Concept Videos
Drug Toxicity: Allergic Reactions
Chronic Kidney Disease II: Clinical Manifestations
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Endocarditis II: Clinical Features of Infective Endocarditis
Bioactivation and Tissue Toxicity
Therapeutic Drug Monitoring: Affecting Factors

